an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law
In the long, unresolved argument over who holds authority over a woman's body and medical choices, a federal appeals court in New Orleans has drawn a new boundary — ruling that mifepristone, the most commonly used abortion medication in America, may no longer travel through the mail to reach those who need it. The 5th Circuit's unanimous decision, rooted in Louisiana's conception of personhood and its state abortion ban, effectively dismantles more than two decades of FDA regulatory evolution. With the drugmaker already petitioning the Supreme Court for emergency relief, the nation once again finds itself waiting for nine justices to determine the shape of a right that millions believed settled — and then lost.
- A single Friday ruling from New Orleans erased two decades of FDA policy overnight, requiring that mifepristone be dispensed only in person by specially certified physicians — a logistical wall for millions of patients.
- The decision lands hardest on those already most vulnerable: rural residents hours from the nearest clinic, survivors of intimate partner violence who cannot safely travel, and people with disabilities who depend on telemedicine to access care.
- Danco Laboratories filed an emergency Supreme Court petition by Saturday morning, warning that the ruling injects 'immediate confusion and upheaval' into medical decisions that are, by nature, measured in days — not court calendars.
- The Trump administration's FDA has quietly launched a new safety review of mifepristone, but admitted in court it cannot say when it will conclude — a fog of uncertainty the appeals court acknowledged and then stepped past anyway.
- Abortion rights advocates called the ruling a step toward a de facto national ban, arguing that since Roe's 2022 fall, mail-order access has become the primary lifeline for people in states where abortion is already illegal — and this decision cuts it.
On a Friday in May, the 5th U.S. Circuit Court of Appeals handed down a unanimous ruling that mifepristone — the abortion pill used by hundreds of thousands of Americans each year — could no longer be mailed to patients. It would have to be dispensed in person, at a clinic, by a specially certified physician. In a single decision, more than two decades of FDA regulations permitting remote prescription and distribution were overturned.
By Saturday morning, Danco Laboratories, the drug's manufacturer, had filed an emergency petition with the Supreme Court asking it to block the ruling while legal challenges continued. The company argued the decision injected immediate chaos into time-sensitive medical choices — and that the disruption was the most significant to abortion policy since the Supreme Court eliminated the constitutional right to abortion in 2022.
The appeals court grounded its reasoning in Louisiana's state abortion ban and its declaration that life begins at conception. The judges found that FDA mail-order rules had effectively allowed out-of-state prescribers to place the drug in the hands of Louisiana residents in defiance of state law. The case had been brought by Louisiana's attorney general and a woman who claimed she had been coerced into taking the medication — together, they sought to roll back FDA rules to their pre-2020 form.
Mifepristone has been on the market since 2000. Over more than two decades of monitoring and study, FDA officials under President Biden concluded the drug was safe enough to be used without direct medical supervision, and during the COVID-19 pandemic, the in-person requirement was dropped entirely. The Trump administration's FDA has since announced a new safety review, though it admitted in court filings it could not say when that review would conclude.
Advocates for abortion access responded with alarm. The ACLU called the ruling shameless and warned that losing mail-order access would fall hardest on people in rural areas, survivors of intimate partner violence, and those with disabilities who rely on telemedicine. Since the fall of Roe, mail-order prescriptions had quietly become a primary means of abortion access — including for people in states where the procedure is banned. The appeals court's decision threatened to sever that lifeline, and the question now moved to a Supreme Court whose conservative majority would decide whether to let it stand.
On a Friday in May, a federal appeals court in New Orleans handed down a decision that upended the landscape of abortion access in America. The 5th U.S. Circuit Court of Appeals, in a unanimous ruling, ordered that mifepristone—the abortion pill used by hundreds of thousands of people each year—could no longer be mailed to patients. It would have to be dispensed only in person, at a clinic, by a specially certified physician. The decision overturned more than two decades of FDA regulations that had permitted the drug to be prescribed and distributed remotely.
By Saturday morning, Danco Laboratories, the drugmaker that produces mifepristone, had filed an emergency petition with the Supreme Court asking it to block the appeals court's decision while legal challenges continued. The company argued that the ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions." What had taken shape over a single day was the most significant disruption to abortion policy since the Supreme Court eliminated the constitutional right to abortion in 2022.
The appeals court's reasoning was rooted in Louisiana's state abortion ban. The judges wrote that the FDA's mail-order regulations created "an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law." They cited the state's declaration that "every unborn child is a human being from the moment of conception and is, therefore, a legal person." The ruling reflected a broader legal strategy by abortion opponents: if they could not ban the pill outright, they could restrict how it was distributed, effectively cutting off access to people in states with strict abortion bans.
The case had been initiated by Louisiana's attorney general and a woman who claimed she had been coerced into taking abortion pills. They sought to roll back FDA regulations to their pre-2020 state, when mifepristone could only be prescribed and dispensed in person. A Louisiana federal judge had sided with them in April, though he had stopped short of immediately undoing the regulations. The appeals court took the next step.
Mifepristone has been on the market since 2000. It is typically used in combination with a second drug, misoprostol, to end early pregnancies. The FDA initially imposed strict limits on its distribution because of rare cases of excessive bleeding. But over more than two decades of monitoring, and after reviewing dozens of studies involving thousands of women, FDA officials under President Biden concluded that the drug was safe enough to be used without direct medical supervision. During the COVID-19 pandemic, the agency dropped both the in-person requirement and the requirement that only specially certified physicians could prescribe it.
The Trump administration's FDA has announced it is conducting a new review of mifepristone's safety at the president's direction. In court filings, the agency acknowledged it could not say when that review might be complete and admitted it was still collecting data. The appeals court judges noted this uncertainty but did not let it stop them from ruling.
Advocates for abortion access were swift in their response. The American Civil Liberties Union called the decision a "shameless" packaging of "lies and propaganda." Julia Kaye, an ACLU lawyer, pointed out that losing mail-order access would be especially devastating for people in rural areas, those experiencing intimate partner violence, and people with disabilities who depend on telemedicine. Reproductive Freedom for All called the ruling "one step closer to a national abortion ban" and said Louisiana had built its case on "debunked, junk science."
The Supreme Court's 2022 decision that eliminated the constitutional right to abortion had returned the question of abortion regulation to the states. In the years since, mail-order prescriptions have become a primary way that abortions are provided, including to people living in states with bans. The appeals court's decision threatened to sever that lifeline. Now the question moved to the nation's highest court, where a conservative majority would decide whether to let the ruling stand.
Citas Notables
injects immediate confusion and upheaval into highly time-sensitive medical decisions— Danco Laboratories, in its petition to the Supreme Court
For countless people, especially those who live in rural areas, face intimate partner violence, or live with disabilities, losing a telemedicine option will mean losing access to this vital medication altogether— Julia Kaye, American Civil Liberties Union
La Conversación del Hearth Otra perspectiva de la historia
Why did the appeals court feel it had the authority to override the FDA's own regulations about how a drug should be distributed?
The court framed it as a conflict between federal drug policy and state law. Louisiana argued that the FDA's mail-order rules were effectively nullifying the state's abortion ban—that you can't have a ban if people can just order the pill by mail from out of state. The judges agreed that the regulations created a workaround.
But the FDA is supposed to be the expert on drug safety. Didn't that matter?
Historically, yes. Courts have deferred to the FDA's judgment on safety for decades. But this court was willing to second-guess that deference. They noted that the Trump administration's FDA is doing a new safety review, which gave them cover to say the current regulations might not be final anyway.
What happens to people who need the pill right now, before the Supreme Court decides?
That's the urgent part. If the appeals court ruling stands, anyone seeking mifepristone in Louisiana and several other states covered by that circuit would have to travel to get it in person. For someone in a rural area, or someone in an abusive relationship, or someone without the money or time to travel, that could mean no access at all.
Is there any chance the Supreme Court blocks this decision quickly?
The drugmaker asked for an emergency stay, which suggests they think there's a real risk the ruling could take effect. The Supreme Court's conservative majority has shown willingness to restrict abortion access, but they also have to weigh the chaos of suddenly changing how a widely used drug is distributed.
What's the larger pattern here?
States with abortion bans are finding new ways to enforce them—not just by banning the procedure, but by controlling how medication is delivered. If they can restrict distribution, they don't need to ban the drug itself. It's a strategy that's likely to spread.